Jump to start of content

Complete requirements by 12/31/19 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/19 could result in a change to your certification status.

Breadcrumb trail:

Cardiovascular Board Interventional Cardiology Exam Committee

Expand All | Collapse All

Dominick J. Angiolillo, MD, PhD, Chair

Dominick J. Angiolillo, MD, PhD, ChairDr. Angiolillo, who is board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology, is Professor of Medicine and serves as the Director of Cardiovascular Research, Program Director, of the Interventional Cardiology Fellowship program, and Staff Cardiologist and Interventional Cardiologist at the University of Florida Health System. He joined the University of Florida College of Medicine-Jacksonville in 2004.

Much of Dr. Angiolillo's professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. He has performed seminal studies on platelet function and modulation of antiplatelet drug response, including genetic studies, for which he has received numerous national and international academic recognitions, including being named to Thomson Reuters' 2014 and 2015 list of The World's Most Influential Scientific Minds. He has also been a key investigator in the clinical development of numerous novel antithrombotic agents. His success in obtaining extramural funding has allowed to him to develop one of the most active clinical research centers in the United States.

Dr. Angiolillo has authored more than 300 peer-reviewed articles and 30 book chapters, and he is the editor of his own textbook on antithrombotic medicine. He has also been invited to deliver numerous lectures across the globe. In addition to holding active membership in many cardiovascular societies in the Unites States and Europe, Dr. Angiolillo is on the editorial board of numerous cardiovascular journals and acts as a scientific reviewer for many major journals and extramural funding agencies, including the National Institutes of Health and other federal funding agencies in several European countries.

Dr. Angiolillo graduated summa cum laude from the Catholic University of the Sacred Heart Medical School in Rome, Italy, where he completed training in medicine and cardiology. He subsequently pursued training in interventional cardiology at the Complutense University of Madrid in Spain. Ultimately, he received his doctoral degree in cellular and molecular cardiology.

As of April 2019, Dr. Angiolillo reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Florida, from the following companies:

  • Amgen, for a trial on use of a PCK9 inhibitor.
  • AstraZeneca, for a trial on ticagrelor.
  • Bayer, for a trial on use of a low dose novel oral anticoagulant.
  • CeleNova, for a trial on stents.
  • Chiesi, for a trial on cangrelor.
  • CSL Behring, for trials on raising HDL cholesterol.
  • Daiichi Sankyo, for a trial of edoxaban use in patients with coronary artery disease.
  • Idorsia, for a trial on a new antiplatelet.
  • Janssen, for a trial on rivaroxaban.

Service on data and safety monitoring boards for the following company, with compensation as listed:

  • CeloNova, on stent trial, receiving honoraria.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • Amgen, advising on evolocumab, receiving reimbursement for travel and honoraria.
  • AstraZeneca, advising on ticagrelor, receiving reimbursement for travel and honoraria.
  • Bayer, advising on a new formulation of aspirin, receiving reimbursement for travel and honoraria.
  • Boehringer Ingelheim, advising on dabigatran, receiving reimbursement for travel and honoraria.
  • Bristol-Myers Squibb, advising on apixaban, receiving reimbursement for travel and honoraria.
  • Daiichi Sankyo, advising on edoxaban, receiving reimbursement for travel and honoraria.
  • Haemonetics, advising on a platelet functional device, receiving honoraria.
  • Janssen, advising on rivaroxaban, receiving reimbursement for travel and honoraria.
  • PlX Pharma, advising on a new formulation of aspirin, receiving reimbursement for travel and honoraria.
  • Pfizer, advising on apixaban, receiving reimbursement for travel and honoraria.
  • Sanofi, advising on clopidogrel, receiving reimbursement for travel and honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, receiving honoraria:

  • PLx Pharma, for development of a new aspirin formulation.

Work funded by educational grants from industry from the following companies:

  • AstraZeneca, receiving salary support.
  • Bayer, receiving salary support.
  • Sanofi, receiving salary support.

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

  • Janssen, for an acute coronary syndrome lecture.

Teaching in satellite symposia funded by the following company, with compensation for travel expenses and honoraria:

  • Chiesi, for an acute coronary syndrome, percutaneous coronary intervention lecture.

Steven R. Bailey, MD

Steven R. BaileyDr. Steven R Bailey, is a Distinguished Professor of Medicine and Radiology in the Janey and Dolph Briscoe Division of Cardiology at the University of Texas Health Science Center in San Antonio, Texas. He is a Diplomate of the American Board of Internal Medicine with Board certification in Cardiovascular Diseases and Interventional Cardiology. Dr. Bailey's clinical focus is interventional procedures to treat structural and valvular heart disease as well as vascular blockages. He currently has research laboratories that are investigating the effects of NOX subtypes in promoting cardiovascular disease and translational research in the field of nanotechnoloigies and nanosensors.

Dr. Bailey is a Past President of the Society for Cardiovascular Angiography and Interventions (SCAI) and is currently the Editor in Chief of Catheterization and Cardiovascular Interventions (CCI Journal) and is on the editorial board of JACC Intervention and the American Journal of Cardiology. He is a fellow of the American College of Physicians, American College of Cardiology and a Master Fellow of the Society for Cardiovascular Angiography and Intervention. He is a member of the Association of University Cardiologists, Association of Cardiology Professors and the International Andreas Greuntizig Society.

As of July 2018, Dr. Bailey reported the following external relationships:

Funding for clinical trial staff, paid to the University of Texas Science Center in San Antonio, from the following companies:

  • SentreHEART, for a clinical trial of left atrial transcatheter closure.
  • Corvia Medical, for a clinical trial of atrial septal defect for diastolic dysfunction.

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:

  • Boston Scientific, for Phase III/IV studies of drug-eluting stents, receiving reimbursement for travel expenses and honoraria.
  • St. Jude, for a clinical events committee for a left atrial appendage occlusion device, receiving honoraria.

Work as an author or editor for following company, with compensation as listed:

  • Wiley, receiving compensation as editor-in-chief of Catheterization Cardiovascular Interventions.

Grant funding from not-for-profit healthcare-related organizations for clinical research staff, paid to the University of Texas Science Center in San Antonio, from the following organization:

  • Duke University, for a Project Quality Research Institute trial.

James C. Blankenship, MD, MHCM

James C. Blankenship, MD, MHCMDr. Blankenship is a practicing, board certified interventional cardiologist at Geisinger Medical Center in Danville, Pennsylvania; Director of the Geisinger cardiology department and catheterization laboratories; and an Adjunct Professor of Medicine at Temple University Medical College.

He represents the American College of Cardiology (ACC) to the American Medical Association Relative Value Update Committee for the past 12 years and co-chairs the ACC Current Procedural Terminology/Relative Value Update Committee Task Force. Dr. Blankenship is immediate past-President of the Society for Cardiovascular Angiography and Interventions and is currently a member of the American Board of Internal Medicine Cardiovascular Board Interventional Cardiology Exam Committee. He has co-authored over 200 scientific abstracts and publications.

Dr. Blankenship earned his medical degree from Cornell University Medical College in New York. He completed his internship, residency and cardiology fellowship at the University of Michigan. In 2014, he received his master's degree in healthcare management from the Harvard School of Public Health.

As of February 2019, Dr. Blankenship reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Geisinger Medical Center, from the following companies:

  • Abbott, for a trial on absorbable stents.
  • GlaxoSmithKline, for a trial of post-percutaneous coronary intervention drugs to decrease adverse events.
  • Therox, for a trial of super-saturated oxygen to minimize reperfusion injury following heart attack.
  • Sinomed, for a study of a new stent for coronary artery disease.
  • Medinol, for a study of a new stent for coronary artery disease.
  • Boston Scientific, for a study of a new stent for coronary artery disease.

Post-marketing clinical research, paid to Geisinger Medical Center, from the following companies:

  • Abbott, for a trial on patent foramen ovale closure.

Dr. Blankenship serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Cardiology, co-Chair of committee advising the ACC on valuation of physician services, receiving reimbursement for travel expenses.
  • American Medical Association, Relative Value Update Committee Member, receiving reimbursement for travel expenses Food and Drug Administration, Circulatory Devices Panel Member, receiving reimbursement for travel expenses and honoraria.

Kirk N. Garratt, MD, MSc

Kirk N. Garratt, MD, MScDr. Garratt is Medical Director, Heart & Vascular Health and the John H. Ammon Chair of Cardiology with Christiana Care Cardiology Consultants, part of the Christiana Care Health System. He is board certified by the American Board of Internal Medicine in Internal Medicine, Cardiovascular Disease and Interventional Cardiology.

In 2005, he joined Northshore-Long Island Jewish (LIJ), Lenox Hill Hospital and Lenox Hill Heart and Vascular Institute in New York, serving as staff interventional cardiologist, Director of Cardiac Intervention, Director of Cardiovascular Research, Director of the interventional cardiovascular fellowship program, and Associate Chair of Cardiovascular Medicine responsible for quality and process improvements. He left the Northshore-LIJ health system in 2015 with the academic title of Professor of Medicine.

Prior to his time at Lenox Hill, Dr. Garratt spent 17 years at Mayo Clinic as Associate Professor of Medicine and consultant for the Department of Internal Medicine and Cardiovascular Diseases. He also served as Chair of the Department of Cardiology at Franciscan-Skemp Medical Center, a Mayo affiliate hospital in La Crosse, Wisconsin. During his time there, Dr. Garratt participated in many Mayo firsts: first directional coronary atherectomy, first laser coronary angioplasty, first coronary stent procedure, and first coronary intervention at a Minnesota hospital without on-site bypass surgery.

Dr. Garratt is actively involved in professional associations and societies, nationally and internationally, as a committee member and leader to advance interventional methods to improve patient care and outcomes. He serves on medical advisory boards, task forces and steering committees, and presents at conferences and symposiums worldwide. He is a member of the American Board of Internal Medicine Cardiology Board Interventional Cardiology Exam Committee. Dr. Garratt is also past President of The Society for Cardiovascular Angiography and Interventions (SCAI).

He has participated in clinical research for more than 30 years, authored more than 300 publications, and is a reviewer and editor for multiple medical journals. Dr. Garratt has earned awards, recognition and grants for academic achievement, research, teaching and mentorship.

Dr. Garratt earned his medical degree from University of California College of Medicine, Irvine. He completed an internship in internal medicine at Los Angeles County-UCLA Harbor Medical Center, a residency in internal medicine at Duke University Medical Center, and a fellowship in clinical cardiology at University of California (UCLA) Center for Health Services. Additionally, Dr. Garratt was part of the inaugural graduating class of interventional cardiology fellows trained at the Mayo Clinic and Foundation in Rochester, Minnesota.

As of July 2018, Dr. Garratt reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:

  • Abbott, for serving on a clinical events adjudication committee for a study on coronary bio-resorbable scaffolds, receiving honoraria.
  • Jarvik Heart, for serving on a clinical events adjudication committee for an implantable artificial heart, receiving reimbursement for travel expenses and honoraria.

Service on a research-related expert panel or advisory board for the following companies, with honoraria:

  • CeloNova, serving as an advisor for ongoing research in Europe.

Teaching in satellite symposia funded by the following companies, with honoraria:

  • CeloNova, for presentation of research regarding the utility of shortened dual antiplatelet therapy in patients with high-risk of bleeding.

Dr. Garratt serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Society for Cardiovascular Angiography and Intervention, President, receiving reimbursement for travel expenses.

Julie M. Miller, MD

Dr. Miller is Associate Professor of Medicine in the Division of Cardiology at the Johns Hopkins University and Hospital. Her position includes clinical care, fellow training, clinical research, mentoring and quality improvement at the Johns Hopkins Hospital, where she also serves as Director of the Vascular Cardiology Program and Director of the Quantitative Angiographic Imaging Laboratory. Dr. Miller is a full-time faculty member at Johns Hopkins University School of Medicine, and is board certified in Cardiovascular Disease and Interventional Cardiology.

Currently, Dr. Miller serves as a member of the American Board of Internal Medicine Cardiovascular Board Interventional Cardiology Exam Committee. She founded and serves as the Executive Director of the Maryland Academic Consortium of Percutaneous Coronary Intervention Appropriateness and Quality. She has recently served on the American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) Management Board, the ACC-NCDR Cath-PCI Leadership Committee, the American Heart Association Clinical Interventional Cardiovascular Care and Peripheral Vascular Cardiology leadership committees. She has served on national expert consensus-writing committees, including Expert Consensus Document for Cardiac Catheterization Laboratories, and Expert Consensus Document for Coronary Computed Tomographic Angiography (CTA). Dr. Miller has published extensively in the fields of general and interventional cardiology.

She is an accomplished clinical investigator, including leading the pivotal international imaging trial of coronary CTA and conventional angiography. She is also a recognized physician educator, invited to deliver numerous lectures nationally. Her most recent endeavors have focused on procedural quality improvement through collaborative peer review and quantitative measures.

Dr. Miller graduated cum laude, with majors in both chemistry and biology, from St. Olaf College. She received her medical degree from the University of Minnesota Medical School. She trained in internal medicine at Duke University, and completed fellowship training in cardiology and interventional cardiology at Duke University.

As of May 2019, Dr. Miller reported the following external relationships:

Dr. Miller serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American College of Cardiology, Member of the National Cardiovascular Data Registry-Cath-PCI Steering Committee, without compensation.

Grant funding for clinical trial expenses and staff, paid to Johns Hopkins University, from the following not-for-profit healthcare-related organizations:

  • American College of Cardiology, to supply contractual services on behalf of Johns Hopkins University and the University of Maryland to perform core laboratory services related to coronary angiography, and PCI to hospitals that choose to participate in the ACC-Accreditation Service and Peer Review.
  • American Heart Association, receiving funding for an angiographic core laboratory that performs angiographic analysis.

Robert N. Piana, MD

Robert N. Piana, MDDr. Piana is Professor of Medicine and Director of the Adult Congenital Interventional Program at Vanderbilt University Medical Center. He is board certified in Cardiovascular Medicine and Interventional Cardiology. He maintains a vigorous clinical enterprise focused on the treatment of coronary artery disease, structural heart disorders (atrial septal defects. patent foramen ovale, pulmonary valve disease), adult congenital heart disease, hypertrophic cardiomyopathy, valvular heart disease, and left atrial appendage closure. He also directs the Clinical Documentation and Coding Excellence Program for the Vanderbilt Heart and Vascular Institute and serves on the Contracts Committee of Vanderbilt University Medical Center.

Dr. Piana has held multiple leadership roles at Vanderbilt University Medical Center. He has served as Associate Chief for the Division of Cardiovascular Medicine, Director of the Cardiac Catheterization Laboratories, Director of Interventional Cardiology, and Fellowship Director for Interventional Cardiology. He is the editor of the Vanderbilt Heart publication for the Vanderbilt Heart and Vascular Institute.

Dr. Piana is a member of the Executive Committee of the American Medical Association CPT Editorial Panel. He previously served as an advisor for the American College of Cardiology (ACC) to the CPT Editorial Panel and chaired the Coding Task Force for the ACC. Dr. Piana is a member of the Publications Committee of the Society for Cardiovascular Angiography and Intervention. He has previously served on the Publications Committee of the National Cardiovascular Data Registry, the Writing Committee of the ACC Interventional Leadership Council, and the ACC Foundation Task Force on Clinical Expert Consensus Documents. He is a reviewer for multiple journals including Journal of the American College of Cardiology (JACC) and JACC Cardiovascular Interventions.

Dr. Piana graduated from Harvard College with a degree in European history and received his medical degree from the University of Pennsylvania. He completed house staff training in internal medicine at Massachusetts General Hospital, followed by fellowships in cardiovascular medicine and interventional cardiology at the Beth Israel Hospital, Boston. Dr. Piana served as Assistant Professor of Medicine at the Brigham and Women’s Hospital prior to moving to Vanderbilt, where he has been on faculty since 2000.

As of August 2018, Dr. Piana reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with compensation for travel and honoraria:

  • Abbott, for assessment of bioresorbable vascular scaffold versus drug eluting stents for coronary disease, assessment of different durations of antiplatelet therapy, and assessment of transcatheter valve implantation for tricuspid valve disease, receiving reimbursement for travel expenses and honoraria.
  • Medtronic, for assessment of a drug-coated balloon for coronary intervention, receiving honoraria.

Dr. Piana also reported receiving compensation from Cardiovascular Peer Review for completing quality reviews of cardiac catheterization laboratories.

Syed T. Rab, MD

Syed T. Rab, MDDr. Rab is a Professor and an Interventional Cardiologist at Emory University in Atlanta, Georgia. He received his Medical degree in 1979 from the University of Karachi Pakistan. Between 1983 and 1986 he completed residency training in Internal Medicine at the Henry Ford Hospital in Detroit, Michigan. He trained at Emory University between 1986-1990 in Cardiology and Interventional Cardiology and joined its faculty in 1988 where he is extensively involved in the training and teaching of general cardiology and interventional cardiology fellows. He is certified by the American Board of Internal Medicine in Internal Medicine, Cardiology and Interventional Cardiology and is a Fellow of the American College of Cardiology and Society of Coronary Angiography and Interventions.

Dr. Rab currently serves on the Publications Committee and the Leadership Committee of the Interventional Section Leadership Council of the American College of Cardiology, where he is the chair of the complex angioplasty group. He was the former chair of the Interventional Section's publication committee, having authored or coauthored twelve peer reviewed articles on topics of importance to the interventional community.

As of July 2018, Dr. Rab reported the following external relationships:

Dr. Rab serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American College of Cardiology, Leadership Committee Member; Interventional Section Leadership Council Member; Chair, Complex Angioplasty Group, without compensation.

Michael Ragosta, MD

Michael Ragosta, MDDr. Ragosta is a board certified cardiologist and interventional cardiologist and the Kaplan Professor of Medicine and Director, Cardiac Catheterization Laboratories at the University of Virginia Health System in Charlottesville, Virginia. He has more than 20 years of experience as an academic interventional cardiologist and is very active in medical education, clinical research and clinical practice. Clinically, he focuses on complex coronary artery disease, chronic total occlusion intervention, and valvular heart disease, particularly aortic stenosis. As an educator, Dr. Ragosta is Program Director for the Interventional Cardiology Fellowship and teaches medical students, residents and cardiology fellows on a daily basis. He is course director for several continuing medical education programs including the weekly “Cath Conference” and the “Central Virginia Cardiac Catheterization Conference”.

Dr. Ragosta is a member of the American Board of Internal Medicine Cardiovascular Board Interventional Cardiology Exam Committee. He has authored several on-line teaching activities and is the author of several durable teaching publications including “Textbook of Clinical Hemodynamics, Cardiac Catheterization: An Atlas and DVD” and “Cases in Interventional Cardiology”, as well as numerous chapters on various topics in interventional cardiology.

Dr. Ragosta is an active clinical researcher focusing on coronary physiology, novel pharmacology for coronary intervention, high risk coronary intervention and valvular heart disease. He has been a Principal Investigator or co-Principal Investigator for numerous clinical trials involving coronary interventional pharmacology, coronary stents, fractional flow reserve and valvular heart disease. He is the author or co-author of over 100 peer-reviewed articles. He is on the editorial board of Journal of American College of Cardiology: Cardiovascular Interventions and is ad hoc reviewer for numerous prestigious journals. He also serves as Editor in Chief of SCAI.org, the website for the Society for Cardiac Angiography and Intervention.

Dr. Ragosta completed medical school at Brown University, an internal medicine residency at Yale-New Haven Hospital and both cardiology and interventional cardiology fellowships at the University of Virginia Health System.

As of May 2019, Dr. Ragosta reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Virginia, from the following companies:

  • Edwards, for a trial of transaortic valve replacement.
  • Janssen, for a trial of rivaroxaban after transaortic valve replacement.
  • Medtronic, for trials on stents.
  • Sinomed, for trials on stents.
  • Svelte Medical, for a trial on stents.

Industry-supported continuing medical education supported by the following, with compensation for travel expenses:

  • Boston Scientific, for a cardiac catheterization conference.
  • Edwards, for a cardiac catheterization conference.

Providing FDA-required training in the use of devices with reimbursement for travel expenses from the following companies:

  • Abbott, for training on a transcatheter mitral valve replacement treatment.
  • Ancora, for training on a ventricular repair system designed for the treatment of heart failure and functional mitral regurgitation.

Work as an author or editor for following company, with compensation as listed:

  • Elsevier, receiving compensation as an author.